De-labeling of Patients With False Diagnosis of Penicillin Allergy

Overview

The purpose of this study is to estimate the prevalence of penicillin allergy, evaluate the diagnostic value of the allergologic work-up used in the study, and the health effects of penicillin allergy.

Full Title of Study: “Diagnostic De-labeling of Patients With False Diagnosis of Penicillin Allergy: A Tool for Improving Antimicrobial Treatment and Reducing Antimicrobial Resistance”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2023

Detailed Description

Penicillin allergy is the most common of self-reported drug allergies and un-verified penicillin allergy is a significant and growing public health problem. 10% of all patients report penicillin allergy. However, there is large discrepancy between reported penicillin allergy and true allergy. Despite its high prevalence, greater than 90% of such patients are in fact able to tolerate the medication without allergic reactions. In this study patients having a penicillin allergy label will be investigated to confirm or to exclude the allergy diagnosis. The diagnostic value of the allergen test panel and the allergologic work-up will be evaluated. Clinical parameters as well as immunological will be assessed.

Interventions

  • Diagnostic Test: Allergy work-up
    • Allergy work-up
  • Other: Blood samples
    • Blood samples

Arms, Groups and Cohorts

  • Other: Patients labeled as penicillin allergic
    • Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of Penicillin allergy in the studied group
    • Time Frame: up to 4 years
    • Frequency of true penicillin allergy in the study group
  • Negative predictive value of the allergy work- up
    • Time Frame: 3 weeks
    • If the allergy work-up is negative, drug provocation test with penicillin will be performed. The purpose of the drug challenge is to confirm lack of allergy and confirm the negative predictive value of the allergy work-up.

Secondary Measures

  • Use of b-lactams after negative allergy work-up and development of new drug reactions following negative testing.
    • Time Frame: 12 months
    • Patients going through an allergy workup with negative results, will be retrospectively contacted within one year after investigation. Telephone interview where the following questions will be asked:1) “Have you received antibiotic therapy since being seen in the allergy clinic?” 2) “If you have been treated, what drug did you take?” 3) “As a result of this, did you have a reaction to the antibiotics?” “If yes, what kind of reaction have you developed?” 4) “If you didn’t take the drug you were challenged with what was the reason for that?”

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients who are referred to the department of Pulmonary medicine with clinical history suspected of having penicillin allergy. – The control group will be healthy adult volunteers with no history of any personal or family history of drug allergy, atopy, inflammatory or autoimmune diseases. Exclusion Criteria:

  • Systemic reactions such as DRESS, any internal organ involvement – Clinical history of Type II-III hypersensitivity reaction – Severe Type IV hypersensitivity reaction such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, vasculitis, acute generalized exanthematous pustulosis – Chronic idiopathic urticaria on antihistamine maintenance treatment/anti-IgE treatment – Medication which can affect the test outcome – Active signs of an underlying disease such as uncontrolled asthma – Cardiac disease with increased risk of serious anaphylaxis – Pregnancy/Breastfeeding – Reaction within the last 4-6 weeks

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Oslo University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Eva Stylianou, Principal Investigator – Oslo University Hospital
  • Overall Official(s)
    • Eva Stylianou, Phd, Principal Investigator, Oslo University Hospital
  • Overall Contact(s)
    • Eva Stylianou, Phd, 004722118784, eva.stylianou@ous-hf.no

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.